
Each vial contains:
Etoposide ……………………………………….. 100 mg
Excipients q.s. to ………………………………….. 5 ml
Concentrated Solution for infusion
Box of 1 vial x 5 ml
– Etoposide is used alone or in combination with other chemotherapeutic regiments for the treatment of refractory testicular tumors in patients who have already received appropriate surgery, chemotherapy and radiation therapy, and for treatment of small cell lung carcinoma.
Non-hopgkin’s lymphoma, Hodgkin’s lymphoma.
Certain types of leukemia (acute lymphoblastic leukemia and acute myelogenous leukemia).
Ewing’s sarcoma and AIDS-related Kaposi’s sarcoma.
Tight, not exceeding 30°C, protect from light.
– Concentrated solution of etoposide must be diluted before admistration with 0,9% sodium chloride or 5% dextrose injection to obtain a solution containing from 200 to 400 µg/ml (at a concentration above 400 µg/ml, precipitation may be occur).
– Etoposide is administered by slow IV infusion. Etoposide solution should not be admisitered by rapid IV injection because it may be cause hypotension. So, etoposide solution should be infused slowly over a period at least 30-60 minutes.
– Dosage of etoposide must be based on the clinical and hematologic response and tolerance of patient and whether or not other chemotherapy or radiation has been used in order to obtain optimum therapeutic results with minimum adverse effects.
Creatinine clearance | Greater than 50 ml/min | 15 – 50 ml/min |
Etoposide | 100% dosage | 75% dosage |
– Subsequent etoposide dosing should be based on patient tolerance and clinical effect. In patients with creatinine clearance less than 15 ml/minute, further dose reduction should be considered.
Please read carefully the leaflet before using.